Lasmiditan Succinate Drug Asset Due Diligence Report 2026

This Lasmiditan Succinate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Lasmiditan Succinate can convert its Small molecule drug profile and 5-HT1F receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Lasmiditan Succinate (query alias: lasmiditan)
Modality / target	Small molecule drug; 5-HT1F receptor; 5-HT1F receptor agonists
Highest global status	Approved
Originator	Eli Lilly & Co.
Active developers	Eli Lilly Japan KK, Eli Lilly Nederland BV, Ildong Pharmaceutical Co., Ltd.

The MCP disease footprint includes Migraine Disorders. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-UMIN000061371	Phase 4	参加者募集終了‐試験継続中/No longer recruiting	20	内服２時間後の頭痛改善、頭痛消失と有害事象
NCT06267664	Not Applicable	Unknown status	1500	Pain freedom at 2 hours
NCT05903040	Not Applicable	Completed	100	Headache pain freedom at 2 hours post dose during the first attack

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2

Phase 3; n=558; evaluation: not stated. Reported fields: -; Number of Participants With at Least One Treatment Emergent Adverse Events (TEAEs) = 133 Participants ; Number of Participants With at Least One Treatment Emergent Adverse Events (TEAEs) = 109 Participants

Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study)

Not Applicable; n=58; evaluation: Positive. Reported fields: Pain freedom(2-h post-dosing) = 37.0 %

Effectiveness and tolerability of lasmiditan as acute migraine treatment (DART): A real-

Not Applicable; n=55; evaluation: Positive. Reported fields: Adverse Event: Adverse events = Adverse events were reported in 53.1% of attacks, predominantly as dizziness ( n = 11), fatigue ( n = 8) and paraesthesia ( n = 6) ; Adverse Event: Adverse events = Adverse events were reported in 53.1% of attacks, predominantly as dizziness ( n = 11), fatigue ( n = 8) and paraesthesia ( n = 6)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Lasmiditan Succinate addresses Migraine Disorders. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-12-18	Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines	Approved	Financial terms not disclosed
2020-10-30	Eli Lilly and Daiichi Sankyo Enter Commercialization Collaboration in Japan for Anti-CGRP Antibody Galcanezumab	Approved	Financial terms not disclosed
2013-10-22	CoLucid Pharmaceuticals, Inc. and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Improved process for the preparation of lasmiditan”. The milestone feed surfaced a patent-application signal described as “Process for the preparation of crystalline form d of lasmiditan hemisuccinate”. The milestone feed surfaced a patent-application signal described as “An improved process for the preparation of lasmiditan”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO